JBS:NYSEJBS N.V. Analysis
Data as of 2026-05-27 - not real-time
$12.98
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
JBS is trading close to its technical support level, with the 20‑day SMA sitting below the 50‑day SMA, indicating a neutral to slightly bearish trend. The RSI is in oversold territory, suggesting potential short‑term upside, while the MACD histogram remains negative, reinforcing a bearish momentum. Volume has been increasing, adding weight to the price action and hinting at renewed buying interest. The stock’s valuation appears attractive, featuring a low price‑to‑earnings multiple and a price‑to‑book ratio well under two, while the dividend yield is exceptionally high and the payout ratio is modest, underscoring dividend sustainability. Analyst consensus leans strongly toward a buy, with target prices significantly above the current market level, implying considerable upside potential. Fundamentally, the company delivers modest revenue growth and thin margins, but it generates positive operating cash flow and a modest free cash flow cushion. However, the balance sheet is heavily leveraged, reflected in a very high debt‑to‑equity ratio, which could constrain future flexibility. Despite the leverage, the company’s cash reserves provide a buffer against short‑term funding pressures. The consumer defensive sector generally offers resilience, yet the meat processing industry faces regulatory scrutiny and commodity price exposure. Overall, the combination of a deep discount to intrinsic value, robust dividend profile, and improving technical signals supports a bullish outlook, while the debt burden and sector‑specific risks temper enthusiasm.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- oversold RSI indicating potential rebound
- price near technical support level
- increasing trading volume supporting upside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- undervalued valuation metrics (low PE, low P/B)
- high dividend yield with sustainable payout
- analyst consensus of strong buy and elevated target prices
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- elevated debt‑to‑equity ratio limiting financial flexibility
- steady cash flow generation supporting dividend continuity
- moderate growth prospects in a defensive consumer sector
Key Metrics & Analysis
Financial Health
Revenue Growth10.70%
Profit Margin1.98%
P/E Ratio8.0
ROE22.10%
ROA5.60%
Debt/Equity268.23
P/B Ratio1.7
Op. Cash Flow$2.7B
Free Cash Flow$409.6M
Technical Analysis
TrendNeutral
RSI29.3
Support$12.40
Resistance$16.76
MA 20$14.80
MA 50$16.08
MA 200$15.05
MACDBearish
VolumeIncreasing
Fear & Greed Index91.2
Valuation
Target Price$19.56
Upside/Downside50.72%
GradeUndervalued
TypeValue
Dividend Yield10.34%
Risk Assessment
Beta0.52
Volatility36.65%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.